drugset / Trial / NCT00249158

A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia

NCT00249158

Phase 3 Completed 344 enrolled Janssen-Cilag Pty Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to compare the effectiveness of an oral formulation of risperidone (an antipsychotic medication) to that of placebo for treating behavioral and psychological signs and symptoms in dementia (BPSSD), specifically aggression, delusions, and hallucinations, in patients with dementia.

Timeline

Start
1998-03
Primary completion
Completion
2001-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 0.5 mg Oral